After registering, you will receive a confirmation email containing information about joining the webinar. By clicking "Register now" you agree to the processing of your personal data for…
Results from the first prospective study, conducted at the Medical University of Vienna, demonstrating penKid as a discriminatory biomarker for successful liberation from CRRT in cardiac surgery…
Our skilled international team has a breadth of experience in life sciences, disease biology, biotechnology, and clinical in vitro diagnostics and is dedicated to supporting the medical community and…
Through this collaboration, the companies will bring an assay for SphingoTec’s innovative kidney function biomarker, Proenkephalin 119-159 (penKid), to Beckman Coulter’s extensive test menu for use…
SphingoTec announces the successful closing of a Series C financing round. The raised capital will allow the company to reach profitability through sustained and strategic commercialization of its…
SphingoTec introduced together with Boditech Med Inc. (Boditech) at the 42nd AKI & CRRT Course in Vicenza the innovative kidney function biomarker penKid developed by SphingoTec and licensed to…
SphingoTec has established an extended intellectual property portfolio covering markers for acute care conditions such as sepsis, acute heart failure and acute kidney injury.
With the mission of improving patient management in critical care settings, SphingoTec has started a series of collaboration with internationally leading academic and non-academic medical centers.
Next to our Nexus IB10 automated and portable immunoassay system we also provide customized MTP assays and testing services to fulfill the specific requirements of our customers.
